Literature DB >> 7066751

In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.

S V Otton, T Inaba, W A Mahon, W Kalow.   

Abstract

Population data indicate that the genetic control is the same for the oxidation of sparteine and debrisoquine, although whether the level of control is regulatory or enzymatic is not clear. Therefore, the influence of debrisoquine on the rates of in vitro formation of the two dehydrogenated metabolites of sparteine in the 9000 x g supernatant fractions of human liver was examined. The interaction of these two drugs was competitive, indicating that the same form of cytochrome P450 is responsible for their biotransformation. Antipyrine at concentrations as high as 4 mM had no effect on sparteine oxidation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066751     DOI: 10.1139/y82-017

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  12 in total

1.  Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?

Authors:  S Plummer; A R Boobis; D S Davies
Journal:  Arch Toxicol       Date:  1986-02       Impact factor: 5.153

2.  High affinity of quinidine for a stereoselective microsomal binding site as determined by a radioreceptor assay.

Authors:  S V Otton; W Kalow; P Seeman
Journal:  Experientia       Date:  1984-09-15

Review 3.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

4.  Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?

Authors:  G C Kahn; A R Boobis; M J Brodie; E L Toverud; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

5.  Sparteine oxidation polymorphism in Greenlanders living in Denmark.

Authors:  K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

6.  CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.

Authors:  Feng-Xiang Yan; M Chris Langub; Mark A Ihnen; Carlton Hornung; Erkki Juronen; Mary K Rayens; Wei-Min Cai; Peter J Wedlund; Paolo Fanti
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

7.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

Authors:  D A Evans; D Harmer; D Y Downham; E J Whibley; J R Idle; J Ritchie; R L Smith
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

8.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

9.  Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.

Authors:  M Eichelbaum; N M Woolhouse
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.

Authors:  L M Distlerath; F P Guengerich
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.